(2012), examined GHK-Cus modulation of 98 genes linked to antioxidant pathways in skin
Dosing protocols are individualized based on the patient's condition, body weight, and treatment goals
Z68.30 BMI 30.0-30.9, adult Z68.31 BMI 31.0-31.9, adult Z68.32 BMI 32.0-32.9, adult Z68.33 BMI 33.0-33.9, adult Z68.34 BMI 34.0-34.9, adult Z68.35 BMI 35.0-35.9, adult Z68.36 BMI 36.0-36.9, adult Z68.37 BMI 37.0-37.9, adult Z68.38 BMI 38.0-38.9, adult Z68.39 BMI 39.0-39.9, adult Z68.41 BMI 40.0-44.9, adult Z68.42 BMI 45.0-49.9, adult Z68.43 BMI 50.0-59.9, adult Z68.44 BMI 60.0-69.9, adult Z68.45 BMI 70 or greater, adult Note: For pediatric patients aged 2-19 years, BMI percentiles are used: Z68.51 BMI less than 5th percentile for age Z68.52 BMI 5th percentile to less than 85th percentile for age Z68.53 BMI 85th percentile to less than 95th percentile for age Z68.54 BMI greater than or equal to 95th percentile for age 3
The trend establishes this medicine as a preferred choice for hospital and clinic use
Greater bone density : Long-term use of either therapy improves bone density, with benefits from both GH and TRT reaching a peak within the first two to three years
